Mycobacterial diseases and antitumour necrosis factor therapy in USA

Annals of the Rheumatic Diseases

Volumn 72, Issue 1, 2013, Pages 37-42

  Winthrop, K L ^a,b   Baxter, R ^c   Liu, L ^d   Varley, C D ^b   Curtis, J R ^f   Baddley, J W ^f   McFarland, B ^c   Austin, D ^a,e   Radcliffe, L ^e   Suhler, E B ^b,e   Choi, D ^a   Rosenbaum, J T ^a,b   Herrinton, L J ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Portland Veteran's Affairs Medical Center ^*

^d DIVISION OF RESEARCH   (United States)

^e PORTLAND VA MEDICAL CENTER   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ALGORITHM; ANKYLOSING SPONDYLITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CAUCASIAN; CHRONIC KIDNEY DISEASE; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EXPOSURE; ELECTRONIC MEDICAL RECORD; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; INFECTION RISK; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; RISK FACTOR; TUBERCULOSIS; ULCERATIVE COLITIS; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84871061278     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200690     Document Type: Article

References (30)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81. (Pubitemid 32488705)
2. Furst DE, Venkatraman MM, Krishna Swamy BG, et al. Well controlled, double-blind, placebo-controlled trials of classical Ayurvedic treatment are possible in rheumatoid arthritis. Ann Rheum Dis 2011;70:392-3.
3. Wolfe F, Michaud K. A brief introduction to the National Data Bank for Rheumatic Diseases. Clin Exp Rheumatol 2005;23:S168-71. (Pubitemid 46657524)
4. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infl iximab and etanercept? Clin Infect Dis 2005;41 Suppl 3:S199-203. (Pubitemid 41022091)
5. Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 2009;5:405-10.
6. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55. (Pubitemid 36278124)
7. Winthrop KL, Chiller T. Preventing and treating biologic-associated opportunistic infections. Nat Rev Rheumatol 2009;5:405-10.
8. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerging Infect Dis 2009;15:1556-61.
9. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5. (Pubitemid 38608568)
10. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
11. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specifi c risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8.
12. Winthrop KL, Yamashita S, Beekmann SE, et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case fi nding through the Emerging Infections Network. Clin Infect Dis 2008;46:1738-40. (Pubitemid 351706773)
13. Falkinham JO 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol 2009;107:356-67.
14. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An offi cial ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
15. Cassidy PM, Hedberg K, Saulson A, et al. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49:e124-9.
16. Winthrop KL, Baxter R, Liu L, et al. The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf 2011;20:229-35.
17. Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-6.
18. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-82.
19. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002;23:553-67.
20. Marras TK, Chedore P, Ying AM, et al. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax 2007;62:661-6. (Pubitemid 47235003)
21. Maimon N, Brunton J, Chan AK, et al. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 2007;62:739-40. (Pubitemid 47235021)
22. Kwon YS, Kim EJ, Lee SH, et al. Decreased cytokine production in patients with nontuberculous mycobacterial lung disease. Lung 2007;185:337-41. (Pubitemid 350165559)
23. Winthrop KL. Pulmonary disease due to nontuberculous mycobacteria: an epidemiologist's view. Future Microbiol 2010;5:343-5.
24. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
25. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72. (Pubitemid 40852885)
26. British Thoracic Society Standards of Care,Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
27. Canadian Tuberculosis Committee (CTC). Can Commun Dis Rep 2008;34:1-13.
28. Winthrop KL. The Risk and Prevention of Tuberculosis: Screening Strategies to Detect Latent Tuberculosis Among Rheumatoid Arthritis Patients Who Use Biologic Therapy. Int J Adv Rheumatol I 2010;8:43-52.
29. van Ingen J, Boeree M, Janssen M, et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 2007;3:414-9. (Pubitemid 47034543)
30. Reported Tuberculosis in the United States, 2008. http://www.cdc.gov/tb/ statistics/reports/2008/pdf/2008report.pdf (accessed February 2010).